Long‑Term Success Seen in Gene Therapy Trial for Inherited Hearing Loss
A multicentre clinical trial investigating a gene‑based treatment for OTOF‑related deafness has reported sustained benefits up to two and a half years after administration. Researchers administered a single dose of an adeno‑associated viral vector carrying a functional copy of the OTOF gene to children and young adults with profound hearing loss caused by mutations in this gene.
Early assessments showed that approximately 90 % of participants experienced measurable improvements in auditory function, with many gaining the ability to detect speech and environmental sounds that were previously inaudible. Follow‑up audiometric testing conducted at six‑month intervals revealed that these gains remained stable throughout the observation period, indicating durability of the therapeutic effect.
Safety monitoring did not identify any serious adverse events linked to the vector; most reported side effects were mild and transient, such as temporary fever or mild inflammation at the injection site. The trial’s design included rigorous immunosuppression protocols to mitigate immune responses to the viral carrier, which appeared to be effective in maintaining long‑term transgene expression.
Experts in the field describe the outcomes as “impressive,” noting that the durability of hearing improvement surpasses that seen in many other experimental gene therapies for sensory disorders. The results suggest that a single intervention could potentially provide lifelong benefit for patients with this specific form of genetic deafness, reducing reliance on hearing aids or cochlear implants.
The research team plans to expand the study to include older age groups and to evaluate long‑term outcomes beyond three years. Regulatory discussions are already underway regarding pathways for broader clinical approval, with the hope that this approach may eventually serve as a model for treating other inherited forms of hearing loss.
COMMENTS